Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000157886 | SCV000110113 | pathogenic | not provided | 2012-09-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000157886 | SCV000207817 | pathogenic | not provided | 2013-05-28 | criteria provided, single submitter | clinical testing | The W81X mutation in the GLA gene has been reported in one individual with Fabry disease (Shabbeer et al., 2002). W81X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Other nonsense mutations in the GLA gene have been reported in association with Fabry disease. Approximately 60-70% of females with a single GLA mutation have some disease manifestations, and 10% of these individuals present with a disease severity that is similar to that of affected males (Bennett et al., 2002).The variant is found in HCM panel(s). |
Genome- |
RCV001807017 | SCV002054452 | pathogenic | Fabry disease | 2021-07-15 | criteria provided, single submitter | clinical testing |